Exelixis Drug Slows Kidney Cancer In New Chance For Embattled Biotech ...

TheStreet.comExelixis Drug Slows Kidney Cancer In New Chance For Embattled Biotech ...ForbesOn September 2, 2014, shares in Exelixis, a drug maker that has spent two decades trying to turn the early fruits of genetic research into drugs, plunged 48% as it announced that its cancer drug, Cometriq, did not extend survival in patients with ...Exelixis Scores Much-Needed Kidney Cancer Study Win to Boost Drug Sales ...TheStreet.comall 2 news articles »

Share this post